CD8A and ovarian cancer: Labeling sections for CD4+ and CD8+ T cells showed that huPDX3 TILs were primarily CD4+ (CD4+/CD8 average ratio of 4.7 ± 3.3), which correlates with poor survival in patients with ovarian cancer (41).